Seeking to carve out its own niche in the obesity space, Syntis Bio launched today to develop an oral weight-loss treatment that mimics the effects of gastric bypass surgery.
Ipsen and Genfit’s elafibranor will now be marketed as Iqirvo and is the first new medicine approved in nearly a decade for the treatment of the rare liver disease, according to the companies.
The company said its experimental drug was found to be safe and showed some effect in patients with a rare, genetic neurological condition called Huntington’s disease in a part of a mid-stage study.
GSK and other drugmakers asked a Delaware court for permission to appeal a ruling allowing more than 70,000 lawsuits claiming that heartburn drug Zantac causes cancer to go forward.
Outside advisers to the U.S. Food and Drug Administration on Monday voted unanimously that the benefits of Eli Lilly’s experimental Alzheimer’s treatment donanemab outweighed its risks, and agreed that trial data showed it was effective in patients with an early stage of the memory-robbing disease.
In 2024, the pharmaceutical industry finds itself confronting high complexity and competition — embracing innovative strategies to navigate these challenges is paramount to ensuring commercial success.